Which Patients Benefit Most from Tirzepatide for Obesity & OSA?
New research identifies a "strong response endotype" of patients who experience nearly double the sleep apnea improvement from tirzepatide.
Tag: Obesity
All
Latest
All
Latest
Small Clinical Trial: Nutroslim Pep19 Reduces Visceral Fat, Improves Sleep
According to researchers, this occurs due to its effect on the endocannabinoid system.
All
Latest
FDA Approves First Prescription Medication for OSA Patients With Obesity
Indicated for moderate-to-severe OSA patients with obesity, adults taking the medication had at least 25 fewer breathing interruptions each hour as they slept. After one year, up to 50% no longer had symptoms associated with OSA.
Eli Lilly Updates Revenue Guidance, Citing Strong Sales of Zepbound and Mounjaro
The company anticipates 2025 revenue growth fueled by Mounjaro and Zepbound, the first FDA-approved medication for adults with moderate-to-severe OSA and obesity, alongside new medicines and expanded manufacturing capacity.
Read More
UK Tirzepatide Rollout Prioritizes Patients With Highest Clinical Need
NICE has outlined a phased three-year rollout of tirzepatide, with patients already in specialist weight management services among the first to receive the drug.
Read More
Zepbound Approval for OSA a ‘Positive Development’ for Patients and Clinicians, AASM Says
The AASM issued a statement in response to the FDA’s approval of Zepbound for OSA patients with obesity, highlighting its potential as a new treatment option while cautioning about its limitations and the importance of sustained weight loss.
Read More
Adenotonsillectomy Doesn’t Cause Weight Gain in Kids, Study Finds
The results of a clinical trial show no correlation between adenotonsillectomies for sleep-disordered breathing and undesirable weight gain in children, contrary to popular belief.
Read More
Most Providers Want GLP-1s Approved for Sleep Apnea, Barometer Finds
A global survey asked healthcare providers which condition they are most eager to see GLP-1 medications approved for, and sleep apnea emerged as the top choice.
Read More
Vivos Adds Nutraceuticals to Address Oxidative Stress as Part of OSA Treatment
Vivos has partnered with Cellev8 Nutrition to enhance its OSA treatment offerings by offering nutraceuticals that target oxidative stress.
Read More
How OSA, Obesity, and Metabolic Syndrome Interact to Increase Cardiovascular Risks
A new review examines the interconnected relationship between obstructive sleep apnea, obesity, and metabolic syndrome, highlighting their shared risk factors and the impact of treatments on cardiovascular health.
Read More
Disrupted Liver Signals Linked to Overeating in Night Shift Workers
Targeting this liver-brain communication pathway could be a promising approach for weight management in individuals with disrupted circadian rhythms.
Read More
GLP-1 Medications Show Promise as First Drug Therapy for Sleep Apnea
Some sleep specialists are already prescribing GLP-1s to sleep apnea patients with obesity. With a potential OSA indication looming, how could this impact sleep apnea treatment?
Read More
Apnimed to Showcase Study Findings on Obesity Hypoventilation Syndrome
The company will present data from a recent clinical trial on the prevalence and characteristics of obesity hypoventilation syndrome at the European Respiratory Society Congress in Vienna.
Read More
Ignoring Sleep Signals May Harm Health for Overweight People
A study indicates that disruptions in the body’s internal biological clock may contribute to health issues in individuals who are already vulnerable due to excess weight.
Read More
Narcolepsy Medication Lumryz Linked to Weight Loss
Nearly one in five study participants treated with the extended-release sodium oxybate medication experienced clinically meaningful weight loss.
Read More
Clinical Trial to Explore Link Between Weight Loss and Sleep
Skye Bioscience’s upcoming phase 2 trial of nimacimab for obesity will explore the impact of weight loss on sleep quality, utilizing sleep monitoring technology.
Read More
Fitbit Data Reveals Connections Between Sleep and Disease
A study using Fitbit data reveals how sleep duration, quality, and consistency are linked to a wide range of health conditions, including obesity, heart health, and mental well-being.
Read More
Sleep Monitoring Integrated into Phase 2 Obesity Drug Trial
Sleep quality and sleep apnea endpoints will be tracked to better understand the impact of Nimacimab on patients with obesity.
Read More